FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. The Company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat, is an oral small molecule inhibitor of HIF prolyl hydroxylases in Phase 3 clinical development for the treatment of anemia in chronic kidney disease.

FibroGen's second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.

TypePublic
HQSan Francisco, US
Founded1993
Size (employees)423 (est)+17%
Websitefibrogen.com
FibroGen was founded in 1993 and is headquartered in San Francisco, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at FibroGen

Thomas B. Neff

Thomas B. Neff

Chairman, Founder, and Chief Executive Officer
Karen L. Bergman

Karen L. Bergman

Vice President, Investor Relations and Corporate Communications
Christine L. Chung

Christine L. Chung

Senior Vice President, China Operations
Richard Farley

Richard Farley

Vice President, Human Resources
R. Wayne Frost

R. Wayne Frost

Senior Vice President, Regulatory Affairs
Al Y. Lin

Al Y. Lin

Senior Vice President, Drug Development
Show more

FibroGen Office Locations

FibroGen has an office in San Francisco
San Francisco, (HQ)
409 Illinois St
Show all (1)
Report incorrect company information

FibroGen Financials and Metrics

FibroGen Revenue

FibroGen's revenue was reported to be $125.67 m in FY, 2017
USD

Revenue (Q3, 2018)

29.0m

Net income (Q3, 2018)

(42.6m)

EBIT (Q3, 2018)

(42.8m)

Market capitalization (4-Dec-2018)

3.5b

Closing stock price (4-Dec-2018)

41.3

Cash (30-Sep-2018)

566.7m
FibroGen's current market capitalization is $3.5 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

180.8m179.6m125.7m

Revenue growth, %

(1%)

General and administrative expense

44.4m46.0m51.8m

R&D expense

214.1m187.2m196.5m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

16.3m120.6m19.5m28.3m89.3m30.1m26.9m29.0m27.3m31.9m44.0m29.0m

General and administrative expense

10.5m9.7m11.2m11.4m10.4m11.6m11.5m13.4m13.0m15.6m15.1m15.4m

R&D expense

50.5m51.6m52.1m43.7m52.4m40.6m46.7m47.0m50.3m57.0m52.1m56.4m

Operating expense total

61.0m61.2m63.3m55.1m62.8m52.2m58.3m60.4m63.3m72.5m67.2m71.8m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

153.3m173.8m673.7m

Accounts Receivable

15.4m10.4m8.5m

Inventories

4.0m2.9m

Current Assets

200.6m266.5m749.0m
Quarterly
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(85.8m)(61.7m)(126.2m)

Depreciation and Amortization

5.7m6.0m6.1m

Inventories

978.0k1.1m

Accounts Payable

2.0m(298.0k)(714.0k)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(46.4m)10.7m(34.4m)(27.8m)(3.5m)(27.7m)(33.2m)(66.3m)(104.1m)(41.4m)(64.8m)(107.4m)

Depreciation and Amortization

2.8m4.2m1.5m3.0m4.5m1.5m3.1m4.6m1.5m3.1m4.7m

Accounts Payable

2.4m(636.0k)(317.0k)(5.0m)(3.0m)(4.5m)(3.3m)(3.0m)184.0k(2.0m)(2.3m)4.6m

Cash From Operating Activities

58.9m20.7m(17.3m)27.4m25.7m(27.1m)(46.9m)(65.3m)(32.0m)(66.9m)(58.7m)
USDY, 2018

Financial Leverage

1.8 x
Show all financial metrics

FibroGen Operating Metrics

FY, 2016

Facilities

2

Patent Portfolios

4

Phase II Trials Products

1

Phase III Trials Products

1
Show all operating metrics

FibroGen Revenue Breakdown

Embed Graph

FibroGen revenue breakdown by geographic segment: 85.6% from Europe, 14.4% from Japan and 0.1% from Other

Report incorrect company information

FibroGen News and Updates

FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen’s Board of Directors…

FibroGen Reports Third Quarter 2018 Financial Results

—Roxadustat New Drug Applications under Review in China and Japan— —Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019— —Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time—

FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018

Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT)

FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting

SAN FRANCISCO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, and FibroGen China Medical Technology Development Co., Ltd. (FibroGen China), today announced the presentation o…

FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with id…

FibroGen Reports Second Quarter 2018 Financial Results

Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018
Show more
Report incorrect company information

FibroGen Company Life and Culture

Report incorrect company information

FibroGen Frequently Asked Questions

  • When was FibroGen founded?

    FibroGen was founded in 1993.

  • Who are FibroGen key executives?

    FibroGen's key executives are Thomas B. Neff, Karen L. Bergman and Christine L. Chung.

  • How many employees does FibroGen have?

    FibroGen has 423 employees.

  • What is FibroGen revenue?

    Latest FibroGen annual revenue is $125.7 m.

  • What is FibroGen revenue per employee?

    Latest FibroGen revenue per employee is $297.1 k.

  • Who are FibroGen competitors?

    Competitors of FibroGen include GlaxoSmithKline, Bristol-Myers Squibb and AstraZeneca.

  • Where is FibroGen headquarters?

    FibroGen headquarters is located at 409 Illinois St, San Francisco.

  • Where are FibroGen offices?

    FibroGen has an office in San Francisco.

  • How many offices does FibroGen have?

    FibroGen has 1 office.